In summary, we reported a non‐invasive biodegradable brain‐targeted CRISPR/Cas12a nanocapsule to simultaneously target multiple oncogenes (EGFR and PLK1) for effective GBM treatment. This evidence concerns the gene EGFR and glioblastoma.